Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients (HELP)
This study has been completed.
Sponsor:
Hospira, Inc.
Information provided by (Responsible Party):
Hospira, Inc.
ClinicalTrials.gov Identifier:
NCT01169571
First received: July 21, 2010
Last updated: March 20, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to characterize the hemodynamic effects of Precedex (dexmedetomidine (DEX)) during 3 loading-dose paradigms in mechanically ventilated post-surgical subjects in an intensive care setting.
| Condition |
|---|
|
Intensive Care Unit |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Phase 4, Open-Label Study Evaluating the Hemodynamic Effect of Differing Loading Regimens of Precedex in a Post-Surgical Intensive Care Patient Population |
Resource links provided by NLM:
Further study details as provided by Hospira, Inc.:
Primary Outcome Measures:
- Clinically significant hypotension (systolic blood pressure <80 mm Hg, diastolic blood pressure <50 mm Hg). [ Time Frame: First 2 hours of study drug administration ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- The incidence of a CMHA. [ Time Frame: 2 - 24 hours ] [ Designated as safety issue: Yes ]
- Incidence of adverse events (AEs) between the 3 loading-dose paradigms [ Time Frame: Post-DEX 24-hour observation period ] [ Designated as safety issue: Yes ]
- Incidence of paradoxical hypertension [ Time Frame: First 2 hours of the post-DEX observation period ] [ Designated as safety issue: Yes ]
- Incidence of paradoxical hypertension [ Time Frame: 24-hour post-DEX observation period ] [ Designated as safety issue: Yes ]
- Amount of analgesics administered [ Time Frame: 2 hours prior, and for the first 2 hours during, study drug administration ] [ Designated as safety issue: Yes ]
- Amount of sedatives administered [ Time Frame: 2 hours prior, and for the first 2 hours during, study drug administration ] [ Designated as safety issue: Yes ]
| Enrollment: | 373 |
| Study Start Date: | August 2010 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Group I - No loading dose |
| Group II - Loading dose over 10 minutes |
| Group III Loading dose over 20 minutes |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Initially intubated and mechanically ventilated post-surgical adult male and female subjects in an intensive care setting.
Criteria
Inclusion Criteria:
- Subject or the subject's legally authorized representative has voluntarily signed and dated the informed consent document approved by the Research Ethics Board (REB).
- Initially intubated and mechanically ventilated adult post-operative subjects in an intensive care setting (e.g., post operative care unit, post anesthesia care unit, etc.) that are expected to require sedation for at least 2 hours.
- Has an ASA classification of 1, 2, 3 or 4.
If female, subject must be postmenopausal, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least one of the following methods of birth control:
- hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration
- intrauterine device (IUD)
- double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream).
Exclusion Criteria:
- Subjects <18 years of age.
- Subjects with a 2nd degree Mobitz Type II or 3rd degree heart block, unless the subject has a permanent pacemaker or pacing wires are in situ.
- Subjects with a known allergy to DEX.
- Hypotension based on repeat assessments prior to starting study drug defined as SBP <90 mm Hg or DBP <60 mm Hg.
- Pre-existing bradycardia prior to starting study drug defined as HR <50 bpm.
- Subjects who, in the opinion of the Investigator, have any other condition where the risks of DEX would be expected to outweigh its benefits (e.g., cardiogenic shock on >2 vasopressors, death anticipated within 48 hours).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01169571
Locations
| Canada, Alberta | |
| Foothills Medical Center | |
| Calgary, Alberta, Canada, T2N 2T9 | |
| University of Alberta Hospital | |
| Edmonton, Alberta, Canada, TcG 2B7 | |
| Red Deer Regional Hlspital Center | |
| Red Deer, Alberta, Canada, T4N 4E7 | |
| Canada, British Columbia | |
| Vancouver Coastal Health Authority | |
| Vancouver, British Columbia, Canada, V5Z 3P1 | |
| St. Paul's Hospiral | |
| Vancouver, British Columbia, Canada, V6Z 1Y6 | |
| Canada, Nova Scotia | |
| Queen Elizabeth II Health Sciences Center | |
| Halifax, Nova Scotia, Canada, B3H 1V7 | |
| Canada, Ontario | |
| Kingston General Hospital | |
| Kingston, Ontario, Canada, K7L 2V7 | |
| St. Mary's General Hospital | |
| Kitchener, Ontario, Canada, N2M 1B2 | |
| Intermountain Infusion Services and Research Consultants | |
| Thunder Bay, Ontario, Canada, P7B &c& | |
| Toronto General Hospiral | |
| Toronto, Ontario, Canada, M5G 2C4 | |
| Canada, Quebec | |
| CHA Laval Hospiral | |
| Laval, Quebec, Canada, G1V 4G5 | |
| Jewish General Hospital | |
| Montreal, Quebec, Canada, H3T 1E2 | |
| Royal Viuctora Hospital | |
| Montreal, Quebec, Canada, HeA 1A1 | |
| McGill University Health Centre | |
| Montreal, Quebec, Canada, HcG 1A4 | |
| CHU Sherbrooke | |
| Sherbrooke, Quebec, Canada, J1H 5N4 | |
Sponsors and Collaborators
Hospira, Inc.
More Information
No publications provided
| Responsible Party: | Hospira, Inc. |
| ClinicalTrials.gov Identifier: | NCT01169571 History of Changes |
| Other Study ID Numbers: | DEX-10-03 |
| Study First Received: | July 21, 2010 |
| Last Updated: | March 20, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Hospira, Inc.:
|
Initially intubated Mechanically ventilated Post-surgical |
Additional relevant MeSH terms:
|
Dexmedetomidine Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013